Verition Fund Management
VYGR icon

Verition Fund Management’s Voyager Therapeutics VYGR Stock Holding History

Verition Fund Management’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$350K Buy
+100,000
New +$379K ﹤0.01% 1724

Other funds holding VYGR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Verition Fund Management's VYGR Position: Q1 2025 in Review

Verition Fund Management sold out of Voyager Therapeutics (VYGR) in Q1 2025, closing a stake of 13,450 shares — an estimated $76.3K sold.

Verition Fund Management first reported a position in VYGR in Q3 2024 and held it in 2 quarters. The position peaked at $216K in Q3 2024. 116 funds tracked by Wall St. Rank hold VYGR as of Q1 2025.

  • Verition Fund Management reported no remaining Voyager Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Verition Fund Management sold 13,450 Voyager Therapeutics shares in Q1 2025, an estimated $76.3K.
  • Verition Fund Management first reported a position in Voyager Therapeutics in Q3 2024 and held it in 2 quarters.
  • Verition Fund Management's Voyager Therapeutics position peaked at $216K in Q3 2024.
  • 116 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q1 2025.

Based on Verition Fund Management's 13F filing for Q1 2025, filed 15 May 2025.